Ulrik Niels Lassen
Clinical Professor
- 2021
- Published
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
Araujo B. de Lima, V., Hansen, M., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, 25 Mar 2021, In: Frontiers in Oncology. 11, 11 p., 558248.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology
Rohrberg, K. S. & Lassen, Ulrik Niels, 2021, In: Drugs. 81, 4, p. 445-452 8 p.Research output: Contribution to journal › Review › Research › peer-review
- Published
Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
Wick, A., Bahr, O., Schuler, M., Rohrberg, K., Chawla, S. P., Janku, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H. J., Ikeda, M., Ando, Y., Wick, W., Steinbach, J. P., Burger, M. C., Wenger, K., Lassen, U., Sankhala, K. K., Roggia, C., Genvresse, I. & 11 others, , 2021, In: Clinical Cancer Research. 27, 10, p. 2723-2733 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
- 2020
- Published
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply
Subbiah, V., Lassen, Ulrik Niels, Gasal, E., Burgess, P. & Wainberg, Z. A., 1 Nov 2020, In: The Lancet Oncology. 21, 11, p. e516 1 p.Research output: Contribution to journal › Comment/debate › Research
- Published
Total burden of disease in cancer patients at diagnosis—a Danish nationwide study of multimorbidity and redeemed medication
Loeppenthin, K., Dalton, Susanne Oksbjerg, Johansen, Christoffer, Andersen, E., Christensen, Mikkel Bring, Pappot, Helle, Petersen, L. N., Thisted, L. B., Frølich, A., Mortensen, C. E., Lassen, Ulrik Niels, Ørsted, J. & Bidstrup, P. E., 15 Sep 2020, In: British Journal of Cancer. 123, 6, p. 1033-1040 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Subbiah, V., Lassen, Ulrik Niels, Élez, E., Italiano, A., Curigliano, G., Javle, M., De Braud, F., Prager, G. W., Greil, R., Stein, A., Fasolo, A., Schellens, J. H. M., Wen, P. Y., Viele, K., Boran, A. D., Gasal, E., Burgess, P., Ilankumaran, P. & Wainberg, Z. A., 1 Sep 2020, In: The Lancet Oncology. 21, 9, p. 1234-1243 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Distress and perceived information among patients in phase I trials and their relatives: A prospective study
Gad, K. T., Dalton, Susanne Oksbjerg, Envold, P. B., Duun-henriksen, A. K., Lassen, Ulrik Niels, Mau-sørensen, M., Rohrberg, K. S., Spanggaard, I., Von Heymann, A., Høeg, B. L. & Johansen, Christoffer, 1 Sep 2020, In: Annals of Oncology. 31, p. S497 1 p., 591P .Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
- Published
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome
Araujo B de Lima, V., Borch, A., Hansen, M., Draghi, A., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, Apr 2020, In: Cytotherapy. 22, 4, p. 204-213 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
Even, C., Lassen, Ulrik Niels, Merchan, J., Le Tourneau, C., Soria, J. C., Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A. & Massard, C., Apr 2020, In: Investigational New Drugs. 38, 2, p. 402-409Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H-T., Machiels, J-P., Spicer, J. F., Jones, R., Forster, M. D., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., Lassen, U. N. & 1 others, , 15 Mar 2020, In: Clinical Cancer Research. 26, 6, p. 1220-1228 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 4952653
Most downloads
-
490
downloads
Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
233
downloads
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
188
downloads
Hallmarks of glioblastoma: a systematic review
Research output: Contribution to journal › Review › Research › peer-review
Published